Human iPSC generation/reprogramming culture

• Use viable human somatic starting cells such as dermal fibroblasts, peripheral blood or cord-blood-derived cells, or activated circulating T cells, because these cell types have been reprogrammed in published human iPSC studies^[1][3][4][7].

• Use pluripotent-stem-cell culture medium supported by the selected literature, such as E8 medium on vitronectin or other defined human pluripotent stem-cell culture systems, because chemically defined E8/vitronectin conditions supported human iPSC derivation and culture^[6].

• Use Matrigel, feeder cells, or defined vitronectin only when matching the selected published method, because different papers used different attachment and culture systems^[1][2][6].

• Use assays for pluripotency markers reported in the literature, including OCT4, SOX2, NANOG, TRA-1-60, TRA-1-81, SSEA-3, and SSEA-4, and use vector-clearance assays such as anti-Sendai immunostaining or qRT-PCR when Sendai virus vectors are used^[1][2][3].

• Use karyotyping and three-germ-layer differentiation assays to evaluate established clones, because these endpoints were used to characterize human iPSC lines in foundational studies^[1][2].

• Use standard sterile mammalian cell-culture equipment, a CO2 incubator, phase-contrast microscope, centrifuge, biosafety cabinet, and molecular/cytometry platforms compatible with the chosen readouts; the literature supports microscopy-based colony identification, immunostaining or flow-based marker analysis, qRT-PCR for vector detection, and karyotype/differentiation testing as analytical endpoints^[1][2][3][6].

• Prepare healthy, actively growing donor somatic cells before reprogramming, because the cited human reprogramming studies introduced defined factors into cultured fibroblasts, blood-derived cells, or activated T cells rather than into poorly viable cultures^[1][3][4][7].

• Plate cells under the culture conditions specified by the chosen delivery method, and use defined E8/vitronectin culture when following the chemically defined iPSC derivation system^[6].

• Select one literature-supported reprogramming system before beginning: Sendai virus for non-integrating RNA-vector delivery, episomal plasmids for integration-free plasmid reprogramming, or modified mRNA for repeated non-integrating RNA delivery^[3][4][5][6].

• Do not mix parameters across systems unless the combination is directly supported by the same paper^[3][4][5][6].

• Introduce reprogramming factors using one selected method: Sendai virus systems deliver OCT3/4, SOX2, KLF4, and c-MYC-related reprogramming vectors; episomal systems used plasmids including reprogramming factors and, in improved versions, p53 suppression and L-MYC; modified mRNA systems used synthetic modified RNAs to express reprogramming factors repeatedly during culture^[3][4][5].

• After factor delivery, culture cells under pluripotent-stem-cell conditions and monitor for colonies with human embryonic-stem-cell-like morphology; published human iPSC studies selected colonies based on morphology and then confirmed pluripotency by marker expression and differentiation capacity^[1][2][3].

• For Sendai-virus-derived colonies, passage candidate colonies and test loss of viral material by qRT-PCR or anti-Sendai staining, because Sendai studies reported vector clearance during passaging and, for temperature-sensitive vectors, enhanced removal by nonpermissive temperature treatment^[3].

• Pick individual candidate colonies only after they display stable pluripotent-stem-cell-like morphology, expand them clonally, and retain clones that pass identity, pluripotency, vector-clearance, and genomic-integrity checks^{[1][2][3][4][6]}.

• Delete any clone from downstream use if the chosen literature-supported assays show persistent reprogramming vector, absent pluripotency-marker expression, abnormal karyotype, or failure to differentiate toward the three germ layers^[1][2][3].

• Interpret successful reprogramming as the establishment of expandable colonies that express pluripotency markers and show functional pluripotency by differentiation into derivatives of all three germ layers, with normal karyotype reported where tested^[1][2].

• For non-integrating systems, also require evidence that exogenous vector sequences or Sendai viral material are absent or cleared in the final clone, because integration-free or vector-free status was a central endpoint in the Sendai and episomal papers^[3][4].

• Use parental somatic cells as negative controls for pluripotency markers, established human pluripotent stem cells as positive controls when available, and method-specific vector-detection controls when testing residual Sendai virus or plasmid material^[1][2][3][4].

• Report each clone separately rather than pooling all colonies, because reprogramming generates clonal lines that require individual characterization^[1][2][3][4].

Problem: Candidate colonies remain Sendai-positive after early passages.

• Possible Cause: Residual Sendai vector can persist in early iPSC passages.
• Literature-supported Solution: Continue passaging and test by qRT-PCR or anti-Sendai staining; temperature-sensitive Sendai systems reported enhanced vector removal after nonpermissive temperature treatment^[3].

Problem: Reprogrammed clones cannot be classified as bona fide iPSCs.

• Possible Cause: Morphology alone is insufficient to prove pluripotency.
• Literature-supported Solution: Confirm pluripotency-marker expression, normal karyotype when assessed, and three-germ-layer differentiation before accepting a clone^[1][2].

Problem: Integration-free status is uncertain after episomal reprogramming.

• Possible Cause: Episomal approaches require clone-level confirmation that vector sequences are absent.
• Literature-supported Solution: Screen expanded clones for loss of episomal vector sequences and retain only clones confirmed as integration-free or vector-free^[4].